Biogen Idec (BIIB) says its potential MS treatment outperformed a placebo in reducing relapses...

|About: Biogen Inc. (BIIB)|By:, SA News Editor

Biogen Idec (BIIB) says its potential MS treatment outperformed a placebo in reducing relapses in late-stage clinical testing in a Phase 3 clinical trial. Shares off 6% premarket.